- Home
- ATNM vs XCUR Comparison
ATNM vs XCUR Comparison
Compare ATNM & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- XCUR
- Stock Information
- Founded
- ATNM 2000
- XCUR 2011
- Country
- ATNM United States
- XCUR United States
- Employees
- ATNM N/A
- XCUR N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- XCUR Health Care
- Exchange
- ATNM Nasdaq
- XCUR Nasdaq
- Market Cap
- ATNM 49.0M
- XCUR 46.0M
- IPO Year
- ATNM N/A
- XCUR N/A
- Fundamental
- Price
- ATNM $1.63
- XCUR $7.13
- Analyst Decision
- ATNM Strong Buy
- XCUR
- Analyst Count
- ATNM 3
- XCUR 0
- Target Price
- ATNM $4.67
- XCUR N/A
- AVG Volume (30 Days)
- ATNM 238.4K
- XCUR 57.8K
- Earning Date
- ATNM 08-12-2025
- XCUR 08-12-2025
- Dividend Yield
- ATNM N/A
- XCUR N/A
- EPS Growth
- ATNM N/A
- XCUR N/A
- EPS
- ATNM N/A
- XCUR N/A
- Revenue
- ATNM N/A
- XCUR N/A
- Revenue This Year
- ATNM N/A
- XCUR N/A
- Revenue Next Year
- ATNM N/A
- XCUR N/A
- P/E Ratio
- ATNM N/A
- XCUR N/A
- Revenue Growth
- ATNM N/A
- XCUR N/A
- 52 Week Low
- ATNM $1.03
- XCUR $1.44
- 52 Week High
- ATNM $7.16
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- ATNM 50.10
- XCUR 46.65
- Support Level
- ATNM $1.54
- XCUR $6.52
- Resistance Level
- ATNM $1.89
- XCUR $9.50
- Average True Range (ATR)
- ATNM 0.13
- XCUR 0.78
- MACD
- ATNM -0.01
- XCUR -0.01
- Stochastic Oscillator
- ATNM 36.59
- XCUR 28.83
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.